2020
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S, Denkert C, Ellis MJ, Fineberg S, Flowers M, Kreipe HH, Laenkholm AV, Pan H, Penault-Llorca FM, Polley MY, Salgado R, Smith IE, Sugie T, Bartlett JMS, McShane LM, Dowsett M, Hayes DF. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. Journal Of The National Cancer Institute 2020, 113: 808-819. PMID: 33369635, PMCID: PMC8487652, DOI: 10.1093/jnci/djaa201.Peer-Reviewed Original ResearchConceptsBreast cancerClinical utilityKi67 immunohistochemistryInternational Ki67Breast Cancer Working GroupAnalytical validityAssessment of Ki67HER2-negative patientsBreast cancer careCancer Working GroupGroup consensus meetingAdjuvant chemotherapyVisual scoring methodPatient groupCancer careT1-2Prognostic markerPrognosis assessmentPrognosis estimationTreatment decisionsEstrogen receptorHER2 testingConsensus meetingCurrent evidenceClinical validity
2005
Translational Crossroads for Biomarkers
Bast RC, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A. Translational Crossroads for Biomarkers. Clinical Cancer Research 2005, 11: 6103-6108. PMID: 16144908, DOI: 10.1158/1078-0432.ccr-04-2213.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteBiomarker developmentCancer InstituteClinical needAccurate pretreatment stagingUseful laboratory testPrediction of responsePretreatment stagingCancer careDisease progressionOvarian cancerProstate cancerBreast cancerGroups of investigatorsEarly cancer detectionDrug AdministrationTumor typesPromising markerTissue specimensClinical paradigmSpecific markersBiomarkersCancerMultiple biomarkersNew markers